This is the second Orphan Drug Designation for napabucasin, an orally administered agent designed to inhibit cancer stemness pathways by targeting STAT3; the first designation was for gastric cancer including gastroesophageal junction (GEJ) cancer. Read more . . .
Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced that its lead investigational compound, napabucasin, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the treatment of pancreatic cancer.